EMUC 2011 – Results from Phase 1 trial of tivozanib combined with temsirolimus in patients with RCC
Category: Presentation
ASCO 2011: Final Analysis of the Phase 2 Randomized Discontinuation Trial of Tivozanib (AV-951) Versus Placebo in Patients With Renal Cell Carcinoma
ASCO 2011: Final Analysis of the Phase 2 Randomized Discontinuation Trial of Tivozanib (AV-951) Versus Placebo in Patients With Renal Cell Carcinoma
ASCO 2011: Results From a Phase 1 Trial of Tivozanib (AV-951) Combined With Temsirolimus Therapy in Patients With Renal Cell Carcinoma
ASCO 2011: Results From a Phase 1 Trial of Tivozanib (AV-951) Combined With Temsirolimus Therapy in Patients With Renal Cell Carcinoma
ASCO 2011: Phase 2 Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With Non–Small Cell Lung Cancer
ASCO 2011: Phase 2 Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With Non–Small Cell Lung Cancer
ASCO 2011: Phase 1b Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
ASCO 2011: Phase 1b Study of Ficlatuzumab (AV-299), an Anti-Hepatocyte Growth Factor Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
EORTC-NCI-AACR 2010: Tivozanib Biomarker Identifies Tumor-infiltrating Myeloid Cells Contributing to Tivozanib Resistance in Both Preclinical Models and Human Renal Cell Carcinoma
EORTC-NCI-AACR 2010: Tivozanib Biomarker Identifies Tumor-infiltrating Myeloid Cells Contributing to Tivozanib Resistance in Both Preclinical Models and Human Renal Cell Carcinoma
IKCS 2010: Effect of Hypertension, Nephrectomy, and Prior Treatment on the Efficacy of Tivozanib (AV-951) in a Phase 2 Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
IKCS 2010: Effect of Hypertension, Nephrectomy, and Prior Treatment on the Efficacy of Tivozanib (AV-951) in a Phase 2 Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
IKCS 2010: Activity of Tivozanib (AV-951) in Patients With Different Histologic Subtypes of Renal Cell Carcinoma
IKCS 2010: Activity of Tivozanib (AV-951) in Patients With Different Histologic Subtypes of Renal Cell Carcinoma
ASCO 2010: Activity of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma (RCC): Subgroup Analysis From a Phase 2 Randomized Discontinuation Trial (RDT)
ASCO 2010: Activity of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma (RCC): Subgroup Analysis From a Phase 2 Randomized Discontinuation Trial (RDT)
ASCO 2010: Phase 1 Study of SCH 900105, an Anti-Hepatocyte Growth Factor Monoclonal Antibody, as a Single Agent and in Combination with Erlotinib in Patients with Advanced Solid Tumors
ASCO 2010: Phase 1 Study of SCH 900105, an Anti-Hepatocyte Growth Factor Monoclonal Antibody, as a Single Agent and in Combination with Erlotinib in Patients with Advanced Solid Tumors